Cardio-Oncology Updates

From the publishers of JADPRO

Cardio-Oncology Updates

.

Home Cardio-Oncology Basics

Cardio-Oncology Basics

Chapter 4

CV Evaluation of Patients Before and During Cancer Therapy

Download Slides

Chapter 1

7:35

What is Cardio-Oncology?

Chapter 2

11:46

Link Between Cancer, Treatment, and Heart Disease

Chapter 3

8:49

Cardio-Oncology Standards of Care

Chapter 4

4:24

CV Evaluation of Patients Before and During Cancer Therapy

Chapter 5

3:32

Cancer Treatment–Related Cardiotoxicity

Chapter 6

12:33

Breast Cancer Drugs and Cardiotoxicity

Chapter 7

2:07

Cardio-Oncology Basics: Conclusions

Class Categories

Immune Checkpoint Inhibitors

Kinase Inhibitors

HER2-Targeted Therapies

Novel Immunotherapies (CAR-T, BiTE)

Meet the Faculty

Resources

General Cardio-Oncology The Cancer Patient and Cardiology

General Cardio-Oncology The Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio‐Oncology Council of the European Society of Cardiology (ESC)

General Cardio-Oncology Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools From the Cardio-Oncology Study Group of the Heart Failure Association of the European Society

General Cardio-Oncology NCCN Clinical Practice Guidelines in Oncology: Survivorship Version 2.2020

General Cardio-Oncology Cardiovascular and Cancer Risk: The Role of Cardio-Oncology

View More

Videos

Novel Immunotherapies Managing Cardiotoxicity Associated With BiTE Therapy: A Case Study

HER2-Targeted Therapies Monitoring and Management Strategies for HER2-Targeted Therapy–Associated Cardiotoxicity

Immune Checkpoint Inhibitors Managing Cardiotoxicity Associated With Immune Checkpoint Inhibitor Therapy

Kinase Inhibitors Managing Ibrutinib-Associated Cardiotoxicity in CLL: A Case Study

HER2-Targeted Therapies HER2-Targeted Therapies: Cardiotoxicity Incidence

View More